{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:23:27Z","timestamp":1793622207024,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Liver cancer is a highly aggressive malignancy with poor survival rates. Current treatments, including liver transplantation, immunotherapy, and gene therapy, are often limited by late-stage diagnosis and significant side effects, highlighting the urgent need for novel therapeutic agents. In this study, we evaluated the therapeutic potential of Kanglexin (KLX), a novel anthraquinone derivative, in the treatment of liver cancer. In vitro, KLX inhibited the proliferation and migration of HepG2 and Hep3B cells in a dose-dependent manner. Mechanistically, KLX upregulated Z-DNA binding protein 1 (ZBP1) expression, inducing PANoptosis by directly binding to ZBP1, altering its conformation, and reducing its affinity for the E3 ubiquitin ligase ring finger protein 180 (RNF180). This interaction decreased ZBP1 ubiquitination, thereby increasing its stability. Additionally, KLX upregulated the expression of the transcription factor homeobox D10 (HOXD10), which further increased ZBP1 expression. Elevated ZBP1 levels significantly suppressed liver cancer cell proliferation and migration, whereas the inhibitory effects of KLX were reversed upon ZBP1 knockdown. In a xenograft model, KLX significantly inhibited tumor growth with a lower toxicity than oxaliplatin (OXA). In conclusion, KLX promoted PANoptosis in liver cancer cells by upregulating ZBP1 and preventing its degradation, thereby inhibiting liver cancer progression and migration. These findings suggest that KLX is a promising therapeutic agent for liver cancer.<\/jats:p>","DOI":"10.1038\/s41401-025-01528-4","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:39:29Z","timestamp":1743046769000},"page":"2282-2295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["KLX ameliorates liver cancer progression by mediating ZBP1 transcription and ubiquitination and increasing ZBP1-induced PANoptosis"],"prefix":"10.1038","volume":"46","author":[{"given":"Zhuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-ting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-tao","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-lun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-hua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-kun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-man","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"1528_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.7150\/ijbs.89568","volume":"20","author":"X Xin","year":"2024","unstructured":"Xin X, Cheng X, Zeng F, Xu Q, Hou L. The role of TGF-\u03b2\/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci. 2024;20:1436\u201351.","journal-title":"Int J Biol Sci"},{"key":"1528_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0230-0","volume":"8","author":"TB Toh","year":"2019","unstructured":"Toh TB, Lim JJ, Chow EKH. Epigenetics of hepatocellular carcinoma. Clin Transl Med. 2019;8:13.","journal-title":"Clin Transl Med"},{"key":"1528_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41419-024-06542-8","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Zhou Q, Xie DF, Xu Q, Yang T, Wang W, et al. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy. Cell Death. 2024;15:165.","journal-title":"Cell Death"},{"key":"1528_CR4","doi-asserted-by":"publisher","first-page":"10774","DOI":"10.3390\/ijms221910774","volume":"22","author":"N Juaid","year":"2021","unstructured":"Juaid N, Amin A, Abdalla A, Reese K, Alamri Z, Moulay M, et al. Anti-hepatocellular carcinoma biomolecules: molecular targets insights. J Int J Mol Sci. 2021;22:10774.","journal-title":"J Int J Mol Sci"},{"key":"1528_CR5","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.3390\/ijms22157800","volume":"22","author":"S Temraz","year":"2021","unstructured":"Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. Int J Mol Sci. 2021;22:7800.","journal-title":"Int J Mol Sci"},{"key":"1528_CR6","first-page":"267","volume":"73","author":"S Rubens Copia","year":"2021","unstructured":"Rubens Copia S, Roberto Carmagnani P, Beatriz Viesser M, Ahmed OK. Hepatocellular carcinoma immunotherapy. Annu Rev Med. 2021;73:267\u201378.","journal-title":"Annu Rev Med"},{"key":"1528_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03641-y","volume":"20","author":"L Ren","year":"2022","unstructured":"Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, et al. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2\/M phase transition, and PANoptosis. J Transl Med. 2022;20:444.","journal-title":"J Transl Med"},{"key":"1528_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12909","volume":"297","author":"M Zheng","year":"2020","unstructured":"Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020;297:26\u201338.","journal-title":"Immunol Rev"},{"key":"1528_CR9","volume":"168","author":"Y Xiong","year":"2023","unstructured":"Xiong Y. The emerging role of PANoptosis in cancer treatment. Biomedicine. 2023;168:115696.","journal-title":"Biomedicine."},{"key":"1528_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41392-022-00889-0","volume":"7","author":"JF Lin","year":"2022","unstructured":"Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022;7:54.","journal-title":"Signal Transduct Target Ther"},{"key":"1528_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/10717544.2021.1898703","volume":"28","author":"M Song","year":"2021","unstructured":"Song M, Xia W, Tao Z, Zhu B, Zhang W, Liu C, et al. Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. Drug Deliv. 2021;28:594\u2013606.","journal-title":"Drug Deliv"},{"key":"1528_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.molmed.2023.10.001","volume":"30","author":"A Pandeya","year":"2024","unstructured":"Pandeya A, Kanneganti TD. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol Med. 2024;30:74\u201388.","journal-title":"Trends Mol Med"},{"key":"1528_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.2200508","volume":"209","author":"N Pandian","year":"2022","unstructured":"Pandian N, Kanneganti TD. PANoptosis: a unique innate immune inflammatory cell death modality. J Immunol. 2022;209:1625\u201333.","journal-title":"J Immunol"},{"key":"1528_CR14","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1039\/c9tx00240e","volume":"8","author":"Y Niu","year":"2019","unstructured":"Niu Y, Tang E, Zhang Q. Cytotoxic effect of silica nanoparticles against hepatocellular carcinoma cells through necroptosis induction. Toxicol Res. 2019;8:1042\u20139.","journal-title":"Toxicol Res"},{"key":"1528_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41401-019-0307-8","volume":"41","author":"Y Bian","year":"2020","unstructured":"Bian Y, Li X, Pang P, Hu X, Yu S, Liu Y, et al. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. 2020;41:319\u201326.","journal-title":"Acta Pharmacol Sin"},{"key":"1528_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41401-021-00686-5","volume":"43","author":"H Li","year":"2022","unstructured":"Li H, Liu X, Meng Z, Wang L, Zhao L, Chen H, et al. Kanglexin delays heart aging by promoting mitophagy. Acta Pharmacol Sin. 2022;43:613\u201323.","journal-title":"Acta Pharmacol Sin"},{"key":"1528_CR17","first-page":"572637","volume":"11","author":"Y You","year":"2020","unstructured":"You Y, Gao Y, Wang H, Li J, Zhang X, Zhu Z, et al. Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-\u03b21\/ERK1\/2 noncanonical pathway. Front Pharmacol. 2020;11:572637.","journal-title":"Front Pharmacol"},{"key":"1528_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10616-014-9761-9","volume":"67","author":"GH Qiu","year":"2014","unstructured":"Qiu GH, Xie X, Xu F, Shi X, Wang Y, Deng L. Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology. 2014;67:1\u201312.","journal-title":"Cytotechnology."},{"key":"1528_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u20137.","journal-title":"Science."},{"key":"1528_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","volume":"1607","author":"SK Burley","year":"2017","unstructured":"Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. Protein data bank (PDB): the single global macromolecular structure archive. Methods Mol Biol. 2017;1607:627\u201341.","journal-title":"Methods Mol Biol"},{"key":"1528_CR21","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202\u201313.","journal-title":"Nucleic Acids Res"},{"key":"1528_CR22","doi-asserted-by":"publisher","first-page":"771528","DOI":"10.3389\/fonc.2021.771528","volume":"11","author":"W Pan","year":"2021","unstructured":"Pan W, Wang K, Li J, Li H, Cai Y, Zhang M, et al. Restoring HOXD10 exhibits therapeutic potential for ameliorating malignant progression and 5-fluorouracil resistance in colorectal cancer. Front Oncol. 2021;11:771528.","journal-title":"Front Oncol"},{"key":"1528_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s11658-021-00268-7","volume":"26","author":"X Sun","year":"2021","unstructured":"Sun X, Hou L, Qiu C, Kong B. MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer. Cell Mol Biol Lett. 2021;26:20.","journal-title":"Cell Mol Biol Lett"},{"key":"1528_CR24","doi-asserted-by":"publisher","first-page":"e32288","DOI":"10.1016\/j.heliyon.2024.e32288","volume":"10","author":"YZ Li","year":"2024","unstructured":"Li YZ, Deng J, Zhang XD, Li DY, Su LX, Li S, et al. Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1\u03b1 signalling axis in liver cancer. Heliyon. 2024;10:e32288.","journal-title":"Heliyon."},{"key":"1528_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21:294\u2013311.","journal-title":"Nat Rev Clin Oncol"},{"key":"1528_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3892\/mmr.2021.12147","volume":"24","author":"R Xu","year":"2021","unstructured":"Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, et al. LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K\/AKT\/HIF-1\u03b1 pathway. Mol Med Rep. 2021;24:508.","journal-title":"Mol Med Rep"},{"key":"1528_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37542-5","volume":"14","author":"Y Shi","year":"2023","unstructured":"Shi Y, Niu Y, Yuan Y, Li K, Zhong C, Qiu Z, et al. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nat Commun. 2023;14:1932.","journal-title":"Nat Commun"},{"key":"1528_CR28","first-page":"1542","volume":"10","author":"T Lin","year":"2022","unstructured":"Lin T, Hu L, Hu F, Li K, Wang CY, Zong LJ, et al. NET-triggered NLRP3 activation and IL18 release drive oxaliplatin-induced peripheral neuropathy. Cancer. Immunol Res. 2022;10:1542\u201358.","journal-title":"Immunol Res"},{"key":"1528_CR29","doi-asserted-by":"publisher","first-page":"110802","DOI":"10.1016\/j.biopha.2020.110802","volume":"133","author":"X Li","year":"2020","unstructured":"Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK\/SREBP-2\/PCSK9\/LDLR signalling pathway. Biomed Pharmacother. 2020;133:110802.","journal-title":"Biomed Pharmacother"},{"key":"1528_CR30","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1007\/s00210-024-03285-3","volume":"397","author":"J Fender","year":"2024","unstructured":"Fender J, Kl\u00f6cker J, Boivin-Jahns V, Ravens U, Jahns R, Lorenz K. Cardiac glycosides\u201d-quo vaditis?-past, present, and future? Naunyn Schmiedebergs Arch Pharmacol. 2024;397:9521\u201331.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1528_CR31","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1021\/jacs.6b00162","volume":"138","author":"YV Surovtseva","year":"2016","unstructured":"Surovtseva YV, Jairam V, Salem AF, Sundaram RK, Bindra RS, Herzon SB. Characterization of cardiac glycoside natural products as potent inhibitors of DNA double-strand break repair by a whole-cell double immunofluorescence assay. J Am Chem Soc. 2016;138:3844\u201355.","journal-title":"J Am Chem Soc"},{"key":"1528_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03605-y","volume":"12","author":"X Li","year":"2021","unstructured":"Li X, Zheng J, Chen S, Meng F, Ning J, Sun S. Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK\/elF2\u03b1\/ATF4\/CHOP pathway in breast cancer. Cell Death Dis. 2021;12:314.","journal-title":"Cell Death Dis"},{"key":"1528_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/imr.13237","volume":"321","author":"W Xu","year":"2024","unstructured":"Xu W, Liu W, Yang J, Lu J, Zhang H, Ye D. PANoptosis: mechanisms, biology, and role in disease. Immunol Rev. 2024;321:181\u201398.","journal-title":"Immunol Rev"},{"key":"1528_CR34","first-page":"341","volume":"2","author":"M Zheng","year":"2021","unstructured":"Zheng M, Kanneganti TD. Newly identified function of caspase-6 in ZBP1-mediated innate immune responses, NLRP3 inflammasome activation, PANoptosis, and host defense. Biol Chem. 2021;2:341\u20137.","journal-title":"Biol Chem"},{"key":"1528_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23004-3","volume":"12","author":"JY Baik","year":"2021","unstructured":"Baik JY, Liu Z, Jiao D, Kwon HJ, Yan J, Kadigamuwa C, et al. ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer. Nat Commun. 2021;12:2666.","journal-title":"Nat Commun"},{"key":"1528_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3324\/haematol.2020.274480","volume":"107","author":"K Ponnusamy","year":"2021","unstructured":"Ponnusamy K, Tzioni MM, Begum M, Robinson ME, Caputo VS, Katsarou A, et al. The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica. 2021;107:721\u201332.","journal-title":"Haematologica."},{"key":"1528_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05794-0","volume":"14","author":"J Hoff","year":"2023","unstructured":"Hoff J, Xiong L, Kammann T, Neugebauer S, Micheel JM, Ga\u00dfler N, et al. RIPK3 promoter hypermethylation in hepatocytes protects from bile acid-induced inflammation and necroptosis. Cell Death Dis. 2023;14:275.","journal-title":"Cell Death Dis"},{"key":"1528_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48032-7","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Song A, Xie J, Wang YY, Wang WD, Zhang MJ, et al. Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity. Nat Commun. 2024;15:3669.","journal-title":"Nat Commun"},{"key":"1528_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41594-018-0084-y","volume":"25","author":"V Akimov","year":"2018","unstructured":"Akimov V, Barrio-Hernandez I, Hansen SVF, Hallenborg P, Pedersen AK, Bekker-Jensen DB, et al. UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol. 2018;25:631\u201340.","journal-title":"Nat Struct Mol Biol"},{"key":"1528_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrc.2017.105","volume":"18","author":"D Senft","year":"2017","unstructured":"Senft D, Qi J, Ronai ZA. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 2017;18:69\u201388.","journal-title":"Nat Rev Cancer"},{"key":"1528_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1080\/15384101.2023.2205201","volume":"22","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Liu N, Xu T, Song K. RING finger gene 180 inhibits osteosarcoma progression through regulating chromobox homolog 4 ubiquitination. Cell Cycle. 2023;22:1246\u201358.","journal-title":"Cell Cycle"},{"key":"1528_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0316-0","volume":"17","author":"YH Yuan","year":"2019","unstructured":"Yuan YH, Wang HY, Lai Y, Zhong W, Liang WL, Yan FD, et al. Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC\/AKT\/MAPK signaling pathway. Cell Commun Signal. 2019;17:9.","journal-title":"Cell Commun Signal"},{"key":"1528_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0412-9","volume":"9","author":"Y Guo","year":"2017","unstructured":"Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, et al. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma. Clin Epigenetics. 2017;9:116.","journal-title":"Clin Epigenetics"},{"key":"1528_CR44","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1074\/jbc.RA120.013752","volume":"295","author":"S Kesavardhana","year":"2020","unstructured":"Kesavardhana S, Malireddi RKS, Burton AR, Porter SN, Vogel P, Pruett-Miller SM, et al. The Z\u03b12 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development. J Biol Chem. 2020;295:8325\u201330.","journal-title":"J Biol Chem"},{"key":"1528_CR45","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4049\/jimmunol.1701538","volume":"200","author":"T Kuriakose","year":"2018","unstructured":"Kuriakose T, Zheng M, Neale G, Kanneganti TD. IRF1 is a transcriptional regulator of ZBP1 promoting NLRP3 inflammasome activation and cell death during influenza virus infection. J Immunol Rev. 2018;200:1489\u201395.","journal-title":"J Immunol Rev"},{"key":"1528_CR46","doi-asserted-by":"crossref","unstructured":"An N, Luo XM, Zhang M, Yu RL. MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10 directly. Exp Ther Med. 2017;13:79\u201384.","DOI":"10.3892\/etm.2016.3942"},{"key":"1528_CR47","doi-asserted-by":"publisher","unstructured":"Zhang F, Song JL, Wu H, Lin KY, Wang CL, Zeng LH, et al. A novel deacetylase inhibitor KLX suppresses liver fibrosis by deacetylating PPAR\u03b3 through promoting ubiquitination-mediated HDAC1 degradation. Sci China Life Sci. 2025. https:\/\/doi.org\/10.1007\/s11427-024-2827-y","DOI":"10.1007\/s11427-024-2827-y"},{"key":"1528_CR48","doi-asserted-by":"crossref","unstructured":"Zhao YX, Wang ZQ, Ren J, Chen H, Zhu J, Zhang Y, et al. The novel anthraquinone compound Kanglexin prevents endothelial-to-mesenchymal transition in atherosclerosis by activating FGFR1 and suppressing integrin \u03b21\/TGF\u03b2 signaling. Front Med. 2024;18:1068\u201386.","DOI":"10.1007\/s11684-024-1077-3"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01528-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:36:51Z","timestamp":1757158611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01528-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01528-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}